Literature DB >> 11687716

Dynamic contrast-enhanced magnetic resonance imaging in oncology.

M V Knopp1, F L Giesel, H Marcos, H von Tengg-Kobligk, P Choyke.   

Abstract

Dynamic contrast-enhanced MRI (DCE-MRI) is the acquisition of sequential images during the passage of a contrast agent within a tissue of interest. The current gadolinium chelate agents enable visualization of lesion vasculature and, due to their small size, can be used to assess vascular permeability. Recent studies demonstrated that the temporal evolution of gadolinium-induced signal intensity changes within a tumor reflects the angiogenic properties of the tumor. These can be quantified and are related to vascular density and other angiogenic characteristics of lesions, such as the level of vascular endothelial growth factor. DCE-MRI provides noninvasive characterization of antiangiogenic response of tumor during therapeutic intervention to monitor and predict response. This article reviews the fundamental pathophysiological basis of DCE-MRI and the technical aspects necessary for successful implementation DCE-MRI. The role of DCE-MRI in tumor detection, characterization, and therapy monitoring is reviewed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11687716     DOI: 10.1097/00002142-200108000-00006

Source DB:  PubMed          Journal:  Top Magn Reson Imaging        ISSN: 0899-3459


  36 in total

1.  Benign prostate hyperplasia: evaluation of treatment response with DCE MRI.

Authors:  J T Heverhagen; H von Tengg-Kobligk; K T Baudendistel; G Jia; H Polzer; H Henry; A L Levine; T J Rosol; M V Knopp
Journal:  MAGMA       Date:  2004-06-23       Impact factor: 2.310

2.  MR evaluation of sinonasal angiomatous polyp.

Authors:  Y Z Wang; B T Yang; Z C Wang; L Song; J F Xian
Journal:  AJNR Am J Neuroradiol       Date:  2011-12-22       Impact factor: 3.825

3.  A grid-based image archival and analysis system.

Authors:  Shannon Hastings; Scott Oster; Stephen Langella; Tahsin M Kurc; Tony Pan; Umit V Catalyurek; Joel H Saltz
Journal:  J Am Med Inform Assoc       Date:  2005-01-31       Impact factor: 4.497

4.  Volumetric analysis of mice lungs in a clinical magnetic resonance imaging scanner.

Authors:  Johannes T Heverhagen; Horst K Hahn; Michael Wegmann; Udo Herz; Chastity D Shaffer Whitaker; Volker Matschl; Heiko Alfke
Journal:  MAGMA       Date:  2004-10-05       Impact factor: 2.310

Review 5.  Imaging tumour angiogenesis.

Authors:  Tony Jeswani; Anwar R Padhani
Journal:  Cancer Imaging       Date:  2005-12-01       Impact factor: 3.909

6.  Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478.

Authors:  Bénédicte F Jordan; Matthew Runquist; Natarajan Raghunand; Amanda Baker; Ryan Williams; Lynn Kirkpatrick; Garth Powis; Robert J Gillies
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

Review 7.  Update on brain tumor imaging: from anatomy to physiology.

Authors:  S Cha
Journal:  AJNR Am J Neuroradiol       Date:  2006-03       Impact factor: 3.825

8.  In vivo assessment of aqueous humor dynamics upon chronic ocular hypertension and hypotensive drug treatment using gadolinium-enhanced MRI.

Authors:  Leon C Ho; Ian P Conner; Chi-Wai Do; Seong-Gi Kim; Ed X Wu; Gadi Wollstein; Joel S Schuman; Kevin C Chan
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-24       Impact factor: 4.799

9.  Validation of dynamic contrast-enhanced magnetic resonance imaging-derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model.

Authors:  Moira C Ferrier; Hemant Sarin; Steve H Fung; Bawarjan Schatlo; Ryszard M Pluta; Sandeep N Gupta; Peter L Choyke; Edward H Oldfield; David Thomasson; John A Butman
Journal:  Neoplasia       Date:  2007-07       Impact factor: 5.715

10.  RGS4 controls renal blood flow and inhibits cyclosporine-mediated nephrotoxicity.

Authors:  A Siedlecki; J R Anderson; X Jin; J R Garbow; T S Lupu; A J Muslin
Journal:  Am J Transplant       Date:  2009-12-02       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.